Erasca Inc (ERAS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Erasca Inc (ERAS) Competitors
The companies most similar to Erasca are CG Oncology, Inc. Common stock (CGON), Crispr Therapeutics AG (CRSP) and Travere Therapeutics (TVTX). By market cap, Erasca ranks 3rd of the 13 companies on this page; Abivax SA American Depositary Shares (ABVX) is the largest at $7.67B.
Peer Comparison
ERAS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Erasca (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Crispr Therapeutics AG (CRSP) | $4.10B | N/A | 155.2x | 0.0% | -20.3% | 1325.0% | 0.00% |
| Travere Therapeutics Inc (TVTX) | $4.86B | N/A | 7.2x | -18.7% | -23.1% | 36.2% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| Enliven Therapeutics Inc. (ELVN) | $3.59B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tango Therapeutics Inc (TNGX) | $4.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Edgewise Therapeutics Inc (EWTX) | $5.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Arcus Biosciences Inc (RCUS) | $2.51B | N/A | 21.5x | 0.0% | -75.9% | -65.4% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Arcutis Biotherapeutics Inc (ARQT) | $3.57B | 129.3x | 7.0x | 5.9% | 7.8% | 45.1% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| Xencor Inc (XNCR) | $2.78B | N/A | 13.5x | -58.8% | -17.3% | 454.9% | 0.00% |
| Peer median | $4.21B | 129.3x | 11.3x | 0.0% | -22.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Erasca, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CG Oncology, Inc. Common stock (CGON) | CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070... | CGON competitors |
| Crispr Therapeutics AG (CRSP) | CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. | CRSP competitors |
| Travere Therapeutics Inc (TVTX) | Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification... | TVTX competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| Enliven Therapeutics Inc. (ELVN) | Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare... | ELVN competitors |
| Tango Therapeutics Inc (TNGX) | Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation... | TNGX competitors |
| Edgewise Therapeutics Inc (EWTX) | Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. | EWTX competitors |
| Arcus Biosciences Inc (RCUS) | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. | RCUS competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Arcutis Biotherapeutics Inc (ARQT) | Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. | ARQT competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| Xencor Inc (XNCR) | Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed... | XNCR competitors |
Frequently Asked Questions About ERAS
Who are Erasca's main competitors?
The companies most similar to Erasca include CG Oncology, Inc. Common stock (CGON), Crispr Therapeutics AG (CRSP), Travere Therapeutics (TVTX), Abivax SA American Depositary Shares (ABVX) and Enliven Therapeutics (ELVN), listed from the closest match.
Who is Erasca's biggest competitor?
Abivax SA American Depositary Shares (ABVX) is the largest of the similar companies at $7.67B; CG Oncology, Inc. Common stock (CGON) is the closest match by business profile, size, sector and industry.
How does ERAS stock compare with its competitors?
ERAS' net margin is 0.0% against a peer median of 0.0%.
Which of Erasca's competitors pays a higher dividend?
Erasca pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Erasca bigger than its competitors?
No. Erasca is 3rd by market cap among the 13 companies on this page; the largest is Abivax SA American Depositary Shares (ABVX) at $7.67B.
ERAS pages: Overview, Earnings, Forecast, Financials, Competitors